Actinium Pharmaceuticals (ATNM) Cash from Operations (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Cash from Operations of 5870000.0 for Q1 2026, up 22.5% year-over-year from 4791914.21 in Q1 2025, and down 10.99% quarter-over-quarter from 5289000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Cash from Operations (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Cash from Operations for 17 consecutive years, with 5870000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 22.5% year-over-year to 5870000.0; the TTM figure through Mar 2026 stood at 22876000.0 (up 31.25% YoY), while the FY2025 annual figure was 24580000.0, up 25.68% from the prior year.
- Cash from Operations retreated to 5870000.0 in Q1 2026 per ATNM's latest filing, from 5289000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 27918000.0 in Q2 2022 and bottomed at 15077000.0 in Q1 2023.
- Historically, Cash from Operations has averaged 6012529.41 across 5 years, with a median of 7374000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cash from Operations surged 709.03% — and 2023, when it plunged 160.8%.
- Actinium Pharmaceuticals' Cash from Operations stood at 7778000.0 in 2022, then rose by 3.7% to 7490000.0 in 2023, then rose by 23.22% to 5751000.0 in 2024, then climbed by 8.03% to 5289000.0 in 2025, then fell by 10.99% to 5870000.0 in 2026.
- Business Quant data shows ATNM's Cash from Operations at 5870000.0 in Q1 2026, 5289000.0 in Q4 2025, and 6325000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | -5.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.18 Mn |
| Jun 30, 2026 | -5.18 Mn |
| Mar 31, 2026 | -5.87 Mn |
| Mar 31, 2026 | -5.87 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Sep 30, 2025 | -6.33 Mn |
| Sep 30, 2025 | -6.33 Mn |
| Jun 30, 2025 | -5.39 Mn |
| Jun 30, 2025 | -5.39 Mn |
| Mar 31, 2025 | -7.57 Mn |
| Mar 31, 2025 | -7.57 Mn |
| Dec 31, 2024 | -5.75 Mn |
| Dec 31, 2024 | -5.75 Mn |
| Sep 30, 2024 | -11.98 Mn |
| Sep 30, 2024 | -11.98 Mn |
| Jun 30, 2024 | -7.97 Mn |
| Jun 30, 2024 | -7.97 Mn |
| Mar 31, 2024 | -7.37 Mn |
| Mar 31, 2024 | -7.37 Mn |